Biomerica, Inc. (BMRA)
- Previous Close
0.7247 - Open
0.7700 - Bid 0.7077 x 100
- Ask 0.7340 x 100
- Day's Range
0.7200 - 0.7800 - 52 Week Range
0.7000 - 2.1300 - Volume
48,550 - Avg. Volume
57,991 - Market Cap (intraday)
12.145M - Beta (5Y Monthly) -1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3700 - Earnings Date Apr 15, 2024 - Apr 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
www.biomerica.comRecent News: BMRA
Performance Overview: BMRA
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BMRA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BMRA
Valuation Measures
Market Cap
12.21M
Enterprise Value
7.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.25
Price/Book (mrq)
1.56
Enterprise Value/Revenue
1.43
Enterprise Value/EBITDA
-1.23
Financial Highlights
Profitability and Income Statement
Profit Margin
-117.42%
Return on Assets (ttm)
-43.02%
Return on Equity (ttm)
-92.05%
Revenue (ttm)
5.41M
Net Income Avi to Common (ttm)
-6.35M
Diluted EPS (ttm)
-0.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
5.32M
Total Debt/Equity (mrq)
11.04%
Levered Free Cash Flow (ttm)
-2.69M